Arc­turus slides on PhI­II Covid-19 vac­cine da­ta, sig­ni­fy­ing the strug­gle in pro­duc­ing fol­low-up shots

As Covid-19 vac­cine de­mand sags in the US with on­ly about a third of adults hav­ing re­ceived their first boost­er shot, new da­ta just don’t get in­vestors ex­cit­ed the way they used to.

The lat­est ex­am­ple is Arc­turus Ther­a­peu­tics, which tout­ed re­sults from a “Phase I/II/III study” ear­ly Wednes­day say­ing its self-am­pli­fy­ing mR­NA vac­cine proved 55% ef­fec­tive at stop­ping symp­to­matic Covid-19 in­fec­tion and 95% ef­fec­tive at pre­vent­ing se­vere dis­ease. With the lat­ter num­bers reach­ing sim­i­lar lev­els to those of al­ready-au­tho­rized shots, Arc­turus was like­ly hop­ing it could gen­er­ate some ex­cite­ment to push its pro­gram for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER